— Know what they know.
Not Investment Advice

NVCT NASDAQ

Nuvectis Pharma, Inc.
1W: -10.4% 1M: -11.4% 3M: -10.9% YTD: +116.7% 1Y: +197.4% 3Y: +100.7%
$18.44
-0.05 (-0.27%)
 
Weekly Expected Move ±9.8%
$16 $18 $20 $22 $24
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 34 · $602.0M mcap · 21M float · 1.35% daily turnover · Short 78% of daily vol
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -21.73.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Income Trends

Revenue
$0 +0.0% ▲
Gross Profit
$0 +0.0% ▲
Operating Income
-$28M -38.9% ▼
Net Income
-$26M -39.2% ▼
EPS (Diluted)
$-1.32 -18.9% ▼
EBITDA
-$28M -45.1% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$0$0$0$0$0
YoY Growth+0.0%+0.0%-100.0%+0.0%+0.0%
Cost of Revenue$0$0$0$0$0
Gross Profit$0$0$0$0$0
Gross Margin—————
R&D Expenses$10M$13M$15M$13M$18M
SG&A Expenses$3M$6M$8M$7M$9M
Operating Expenses$13M$19M$23M$20M$28M
Operating Income-$13M-$19M-$23M-$20M-$28M
Operating Margin—————
Interest Expense$0$0$0$0$0
Income Before Tax-$13M-$19M-$22M-$19M-$26M
Tax Expense$0$0$0$0$0
Net Income-$13M-$19M-$22M-$19M-$26M
Net Margin—————
EPS (Diluted)$-1.09$-1.51$-1.43$-1.11$-1.32
EBITDA-$13M-$19M-$23M-$19M-$28M
Shares Outstanding13M13M16M17M22M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms